ABEC Launches ATB-2100 Bioreactor for Advanced Therapy Production
Bioprocess solution provider ABEC has introduced the ATB-2100, a bioreactor system designed to scale the manufacturing of cell and gene therapies.
ABEC has launched the ATB-2100, a new bioreactor platform specifically engineered for the production of advanced therapies, including cell and gene treatments. The system aims to address manufacturing challenges by providing scalable processes for high-density cell cultures.
The adoption of advanced therapies has placed increasing pressure on manufacturing facilities to balance quality with production volumes. By introducing the ATB-2100, ABEC intends to provide manufacturers with a standardized platform that maintains consistency during the transition from pilot phases to commercial production.
As the pharmaceutical sector faces rising costs and regulatory scrutiny, the shift toward flexible, single-use technologies remains a key industry trend. ABEC expects this addition to its product line to support the growing demand for rapid development cycles in the biotechnology sector.